Q-omics provides the consensus-scored TUBD1 profile across patient tissues and cancer cell-line models. TUBD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TUBD1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, TUBD1 RNA expression shows 20,848 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KICH, and UVM as cancer lineages where TUBD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBD1 survival associations across molecular data types. TUBD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBD1 RNA expression–survival associations across cancer types. High TUBD1 expression shows unfavorable associations in LIHC, ACC, LGG and MESO, but favorable associations in KIRC and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TUBD1 RNA expression.
This table summarizes TUBD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TUBD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBD1 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, LUSC and LUAD. The KICH box plot shows higher TUBD1 RNA expression in normal versus tumor tissue (log2 FC = −1.910, t-test p < 0.001).
This table shows molecular features associated with TUBD1 in patient tissues and cancer cell lines. In patient samples, TUBD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
